2002
DOI: 10.1111/j.1939-1676.2002.tb02390.x
|View full text |Cite
|
Sign up to set email alerts
|

MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)

Abstract: The purpose of this retrospective study was to evaluate the efficacy and toxicity of the MOPP chemotherapy protocol (mechlorethamine, vincristine, procarbazine, and prednisone) as a rescue regimen in dogs with lymphoma. One hundred seventeen dogs that had resistance to previously administered chemotherapy were evaluated. Before treatment with MOPP, all dogs received a median of 6 chemotherapy drugs for a median duration of 213 days. Thirty-one percent (36 of 117) had a complete response (CR) to MOPP for a medi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
25
0

Year Published

2006
2006
2022
2022

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 51 publications
(26 citation statements)
references
References 20 publications
(25 reference statements)
1
25
0
Order By: Relevance
“…In particular, GS-9219 is clearly superior to the only other nucleotide analogues for which single-agent response data are available in pet dogs with non-Hodgkin's lymphoma; gemcitabine and cytosine arabinoside have published singleagent response rates of <7% (26,27). Additionally, the median FRD for dogs with relapsed non-Hodgkin's lymphoma observed following GS-9219 monotherapy is nearly double that reported previously in dogs with relapsed non-Hodgkin's lymphoma treated with other single-agent or standard multiagent chemotherapy protocols (16,(28)(29)(30)(31)(32)(33).…”
Section: Discussionmentioning
confidence: 91%
“…In particular, GS-9219 is clearly superior to the only other nucleotide analogues for which single-agent response data are available in pet dogs with non-Hodgkin's lymphoma; gemcitabine and cytosine arabinoside have published singleagent response rates of <7% (26,27). Additionally, the median FRD for dogs with relapsed non-Hodgkin's lymphoma observed following GS-9219 monotherapy is nearly double that reported previously in dogs with relapsed non-Hodgkin's lymphoma treated with other single-agent or standard multiagent chemotherapy protocols (16,(28)(29)(30)(31)(32)(33).…”
Section: Discussionmentioning
confidence: 91%
“…These dogs would typically be expected to have shorter durations of response to rescue chemotherapy than the 3-to 5-month rescue remission durations expected for dogs that relapsed after completion of the induction chemotherapy protocol. 5,[20][21][22][23][24] In addition, because of the dose escalation aspect of the study, some dogs received relatively low doses of temozolomide. Although we did not find a significant relationship between temozolomide dose and duration of response to rescue chemotherapy, the statistical power for detecting such a relationship was low.…”
Section: Discussionmentioning
confidence: 99%
“…CR-2 refers to dogs that achieved a CR, relapsed between days 7 and 28, and subsequently responded to the next MOPP cycle. 16 Partial response (PR) was considered a 450% reduction but o100% reduction in measurable disease for 1 chemotherapy cycle, stable disease (SD) was considered o50% reduction or no change in size of all measurable disease for 1 chemotherapy cycle and progressive disease (PD) was considered a 425% increase in measurable disease or appearance of new neoplastic lesions. In addition, a dog was also considered to have PD if hypercalcemia recurred despite no change in gross disease in a dog that was previously in CR/PR/SD with normal plasma ionized calcium concentration.…”
Section: Assessment Of Responsementioning
confidence: 99%
“…3,4,[13][14][15] The mechlorethamine, vincristine, prednisone, procarbazine (MOPP) chemotherapy protocol (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective protocol for dogs with lymphoma that failed to respond or became refractory to previous chemotherapy. 16 MOPP was originally used in people as a first line chemotherapy protocol for both Hodgkin's and nonHodgkin's lymphoma. 17,18 The protocol induces a complete remission in up to 85% of the humans treated.…”
mentioning
confidence: 99%